1. Home
  2. ACOG

as of 02-27-2026 3:15pm EST

$5.95
$0.05
-0.83%
Stocks Nasdaq

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

Founded: 2000 Country:
Canada
Canada
Employees: N/A City: VANCOUVER
Market Cap: 129.4M IPO Year: N/A
Target Price: $18.00 AVG Volume (30 days): 79.2K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $3.75 - $10.88 Next Earning Date: N/A
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): 132.35%
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

AI-Powered ACOG Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 17 hours ago

AI Recommendation

hold
Model Accuracy: 74.29%
74.29%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Latest Alpha Cognition Inc. News

ACOG Breaking Stock News: Dive into ACOG Ticker-Specific Updates for Smart Investing

All ACOG News

Share on Social Networks: